The polyp biopsy market size is expected to see strong growth in the next few years. It will grow to $2.06 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to AI-assisted biopsy procedures, minimally invasive techniques, expansion of hospital and diagnostic laboratory adoption, integration with imaging and cloud platforms, development of novel biopsy tools. Major trends in the forecast period include colonoscopy biopsy, colposcopy-directed biopsy, esophagogastroduodenoscopy biopsy, laryngoscopy biopsy, endoscopic mucosal resection (emr).
The growing prevalence of colorectal cancer is expected to contribute significantly to the expansion of the polyp biopsy market. Colorectal cancer is a malignant condition that develops in the colon or rectum, originating from abnormal and uncontrolled growth of epithelial cells lining the large intestine. This form of cancer is known for its ability to invade nearby tissues and spread to other parts of the body. The increase in colorectal cancer cases is largely attributed to common dietary habits that are high in processed foods and low in fiber. These habits can cause chronic inflammation, disrupt gut microbiota, and encourage the formation of precancerous growths that may eventually become cancerous. Polyp biopsy plays a critical role in addressing this trend by facilitating early detection and histological examination of abnormal lesions, thereby enabling timely treatment and reducing the risk of disease progression. For example, in 2025, the American Cancer Society, a nonprofit organization based in the United States, estimated that there would be 107,320 new cases of colon cancer and 46,950 new cases of rectal cancer in the country, with approximately 52,900 deaths expected as a result. As such, the rising incidence of colorectal cancer is fueling demand for polyp biopsy procedures.
Key companies in the polyp biopsy market are investing in advanced technologies such as artificial intelligence-assisted detection systems to improve the identification of colorectal polyps and enable earlier recognition of potentially cancerous lesions. An artificial intelligence-assisted detection system is a medical tool that evaluates imaging data in real time to detect abnormalities and generate visual alerts for healthcare providers, assisting them in making informed clinical decisions without delivering therapeutic treatments. For example, in September 2024, Odin Medical Ltd., a medical technology firm based in the United States and affiliated with Olympus Corporation, introduced CADDIE, a cloud-based artificial intelligence endoscopy platform. The CADDIE system analyzes colonoscopy footage in real time, identifying areas that may contain colorectal polyps and allowing clinicians to make better decisions during the examination. Clinical evaluations showed that the system improves the rate of adenoma detection without increasing the time or risk involved in the procedure, demonstrating its effectiveness in supporting early diagnosis and improving patient care.
In October 2024, Caldera Medical, a medical device manufacturer based in the United States, acquired UVision360, Inc. for an undisclosed amount. Through this acquisition, Caldera Medical gains access to UVision360's advanced hysteroscopy technology, including the LUMINELLE Bx system, which enhances the company’s offerings in minimally invasive diagnostic and treatment options for uterine conditions such as polyps, fibroids, and other intrauterine abnormalities. UVision360 is a company based in the United States that develops hysteroscopy and cystoscopy systems, including the LUMINELLE platform.
Major companies operating in the polyp biopsy market are Johnson & Johnson (Ethicon), Medtronic plc, Medline Industries LP, FUJIFILM Holdings Corporation, Stryker Corporation, Becton Dickinson and Company (BD), Boston Scientific Corporation, B. Braun Melsungen AG, Olympus Corporation, STERIS plc, Hologic Inc., CooperSurgical Inc., KARL STORZ SE & Co. KG, Cook Medical, ConMed Corporation, Ambu A/S, Richard Wolf GmbH, INRAD, Acheron Instruments (Pvt) Ltd., Innovia Medical.
North America was the largest region in the polyp biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polyp biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the polyp biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have increased the cost of imported biopsy instruments, endoscopic devices, and consumables, affecting hospitals and diagnostic labs in North America and Europe. Segments such as colonoscopy and EMR are most impacted. Positive effects include encouraging domestic manufacturing and technological innovations in cost-effective biopsy instruments.
The polyp biopsy market research report is one of a series of new reports that provides polyp biopsy market statistics, including polyp biopsy industry global market size, regional shares, competitors with a polyp biopsy market share, detailed polyp biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the polyp biopsy industry. This polyp biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A polyp biopsy is a medical procedure in which a healthcare professional removes a small tissue sample from an abnormal growth, or polyp, on the lining of an organ or body cavity. The sample is examined under a microscope to assess cellular characteristics, detect disease, and support accurate diagnosis and treatment planning. This procedure helps determine the nature of polyps, distinguish between benign and malignant conditions, and provide critical information for guiding clinical management or surveillance strategies.
The primary types of polyp biopsy are colonoscopy, colposcopy-directed biopsy, esophagogastroduodenoscopy, and laryngoscopy. Colonoscopy with polyp biopsy involves inserting a flexible camera (colonoscope) into the colon to visualize the intestinal lining and remove tissue samples for diagnostic evaluation. Techniques include endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), and conventional biopsy. These procedures are distributed through online channels, retail pharmacies, and other outlets, and are applied in areas such as colorectal cancer and gastrointestinal disorders. End-users include hospitals, diagnostic laboratories, and specialty clinics.
The polyp biopsy market consists of revenues earned by entities by providing services such as endoscopic ultrasound (EUS), capsule endoscopy, double-balloon enteroscopy, single-balloon enteroscopy, push enteroscopy, transnasal endoscopy, and transanal endoscopic microsurgery (TEM). The market value includes the value of related goods sold by the service provider or included within the service offering. The polyp biopsy market also includes sales of hot biopsy forceps, cold biopsy forceps, endoscopic snares, polypectomy snares, cytology brushes, biopsy needles (fine-needle aspiration needles, core biopsy needles), and endoscopic ultrasound needles. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
Executive Summary
Polyp Biopsy Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses polyp biopsy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for polyp biopsy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The polyp biopsy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Colonoscopy; Colposcopy-Directed Biopsy; Esophagogastroduodenoscopy2) By Technique: Endoscopic Mucosal Resection (EMR); Endoscopic Submucosal Dissection (ESD); Conventional Biopsy
3) By Application: Colorectal Cancer; Gastrointestinal Disorders; Other Applications
4) By End-User: Hospitals; Specialty Clinics
Subsegments:
1) By Colonoscopy: Diagnostic Colonoscopy; Therapeutic Colonoscopy2) By Colposcopy-Directed Biopsy: Cervical Biopsy; Vaginal Biopsy; Vulvar Biopsy
3) By Esophagogastroduodenoscopy: Diagnostic Esophagogastroduodenoscopy; Therapeutic Esophagogastroduodenoscopy
Companies Mentioned: Johnson & Johnson (Ethicon); Medtronic plc; Medline Industries LP; FUJIFILM Holdings Corporation; Stryker Corporation; Becton Dickinson and Company (BD); Boston Scientific Corporation; B. Braun Melsungen AG; Olympus Corporation; STERIS plc; Hologic Inc.; CooperSurgical Inc.; KARL STORZ SE & Co. KG; Cook Medical; ConMed Corporation; Ambu A/S; Richard Wolf GmbH; INRAD; Acheron Instruments (Pvt) Ltd.; Innovia Medical
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Polyp Biopsy market report include:- Johnson & Johnson (Ethicon)
- Medtronic plc
- Medline Industries LP
- FUJIFILM Holdings Corporation
- Stryker Corporation
- Becton Dickinson and Company (BD)
- Boston Scientific Corporation
- B. Braun Melsungen AG
- Olympus Corporation
- STERIS plc
- Hologic Inc.
- CooperSurgical Inc.
- KARL STORZ SE & Co. KG
- Cook Medical
- ConMed Corporation
- Ambu A/S
- Richard Wolf GmbH
- INRAD
- Acheron Instruments (Pvt) Ltd.
- Innovia Medical
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.5 Billion |
| Forecasted Market Value ( USD | $ 2.06 Billion |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |


